Metagenomic next-generation sequencing testing from the perspective of clinical benefits

Mengyuan Chen,Yingying Cai,Lisha Wang,Yongpo Jiang,Jiao Qian,Jiajia Qin,Jiaqin Xu,Jun Li,Sufei Yu,Bo Shen
DOI: https://doi.org/10.1016/j.cca.2023.117730
IF: 6.314
2023-12-23
Clinica Chimica Acta
Abstract:Background and aims Metagenomic next-generation sequencing (mNGS) provided promising supports to rapid pathogen diagnosis. However, summary of scientific application strategy based on clinical practice study is still necessary for enhancing clinical benefits. Materials and methods We conducted a retrospective analysis of 775 samples from patients with suspected infectious diseases (IDs). Based on final diagnosis, diagnostic performance, clinical relevance and clinical impact of mNGS among various clinical settings were assessed, and influencing factors were deeply explored. Results 84.26 % tests were clinically relevant; sample, but not sequencing, was the influencing factor. 40.77 % tests contributed to positive clinical impact, while 0.13 % and 59.10 % to negative and no impact respectively. mNGS utility in patients with IDs, definite infection site, BALF and CSF contributed to higher positive impacts. Days of empirical treatment before sampling ≤ 5 in ICU and ≤ 2 or between 11 and 20 in non-ICU, and reporting in 2 days brought about higher clinical benefit rates. Characteristic pathogen spectrum between ICU and non-ICU cases were revealed. Conclusions Our findings highlighted clinical benefits from mNGS varied among different clinical settings, and elucidated choices on patients, samples, sampling and reporting time were four key factors. Rational strategy should be concerned to promote scientific application of mNGS and better improve clinical value.
medical laboratory technology
What problem does this paper attempt to address?